Brief: Entera Bio Reports FDA Approval Of IND Application For EB613
10/12/2020 14:54
Dec 10 (Reuters) - Entera Bio Ltd ENTX.O :
* ENTERA BIO ANNOUNCES FDA APPROVAL OF IND APPLICATION FOR
EB613 –
AN ORAL HUMAN PARATHYROID HORMONE (1-34) FOR THE TREATMENT OF
OSTEOPOROSIS
* ENTERA BIO - LOOK FORWARD TO REPORTING FINAL BIOMARKER
DATA IN
Q1 OF 2021 FOR EB613
* ENTERA BIO LTD - LOOK FORWARD TO REPORTING FINAL BONE
MINERAL
DENSITY DATA FROM EB613 TRIAL IN Q2 OF 2021
Source text for Eikon: ID:nGNXbWGFwf
Further company coverage: ENTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Entera Bio
See all newsBrief: Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., As Chief Medical Officer Ahead Of Planned Eb613 Phase 3 Initiation
Corrected: Israel's Entera Bio Q2 net loss widens
NASDAQ RESUMED AT 10:02 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:57 AM
Brief: Entera Bio Announces Pricing Of Oversubscribed $275 Million Private Placement